Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)

Documenti analoghi

• Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
  di: Izumi, Keisuke, et al.
  Pubblicazione: (2015)
• Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response
  di: Kikuchi, Jun, et al.
  Pubblicazione: (2015)
• Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study
  di: Izumi, Keisuke, et al.
  Pubblicazione: (2021)
• A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis
  di: Saito, Shuntaro, et al.
  Pubblicazione: (2017)
• Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
  di: Izumi, Keisuke, et al.
  Pubblicazione: (2015)